Mizuho analyst Salim Syed views the 11% selloff yesterday in shares of Atara Biotherapeutics following the company's Q4 results and a $100M equity shelf as unwarranted. The Street seems to be interpreting the shelf as a negative, and "this makes no sense," Syed tells investors in a research note. The update is "simply clarifying language on milestones timing for 2019 -- not necessarily positive or negative; just more precise language," says the analyst. He believes Atara's story remains unchanged on a fundamental basis. He's a buyer of the stock into the AACR data release and keeps a Buy rating on Atara Biotherapeutics with a $62 price target.